WATER III Trial
Aquablation vs. Laser Enucleation for Large Prostates
Study Title: WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates () in Benign Prostatic Hyperplasia
Citation: Ritter et al., 2025 European Association of Urology (EAU) Abstract Presentation
Sponsor / Document ID: ML0738.A | © 2025 PROCEPT BioRobotics Corporation
Primary Objective: Determine safety and efficacy outcomes comparing Aquablation therapy against transurethral laser enucleation of the prostate (LEP) for the treatment of large prostates ()
Study Design and Methodology
Trial Classification: Investigator-initiated, prospective, randomized and non-randomized trial
Clinical Study Locations: Conducted across study centers located in Germany and the United Kingdom
Prostate Volume Inclusion Criteria: Prostates ranging from to
Patient Arms and Sample Sizes:
Aquablation Therapy Arm: patients
Laser Enucleation of the Prostate (LEP) Arm: patients
Long-Term Durability Plan: Planned follow-up period extending to
Primary Endpoints
Primary Efficacy Endpoint: Reduction in International Prostate Symptom Score (IPSS)
Primary Safety Endpoint:
Occurrence of Clavien-Dindo (CD) grade adverse events
Persistent Clavien-Dindo (CD) grade adverse events, specifically including ejaculatory dysfunction, erectile dysfunction, or urinary incontinence
Key Efficacy and Safety Results at 3 Months
Efficacy Outcomes (IPSS Symptom Reduction):
Aquablation Therapy: IPSS reduction of points
LEP Group: IPSS reduction of points
Functional Outcomes (Peak Urinary Flow Rate / Qmax):
Aquablation Therapy: Peak flow increased from at baseline to at (representing an improvement)
LEP Group: Peak flow increased from at baseline to at
Post-Void Residual (PVR): No significant difference between Aquablation therapy and LEP in PVR reduction
Ejaculatory Dysfunction (evaluated in sexually active patients only):
Aquablation Therapy:
LEP Group:
Stress Urinary Incontinence (evaluated in patients who were pad-free at baseline):
Aquablation Therapy:
LEP Group:
Postoperative Complications and Interventions:
Blood Transfusion Rate: Aquablation vs. LEP
Surgical Takeback Rate: Aquablation vs. LEP
Retreatment Rates: retreatments reported for both treatment modalities at
Author Conclusions and Clinical Findings
Comparative Short-Term Outcomes:
Aquablation therapy and LEP showed no significant difference in short-term IPSS symptom improvement, bleeding risk, and PVR reduction.
Laser Enucleation (LEP) Superiority Domains:
LEP demonstrated superiority over Aquablation therapy in achieving greater prostate volume reduction and higher improvements in peak urinary flow rate ().
Aquablation Therapy Superiority Domains:
Aquablation therapy demonstrated superiority over LEP by maintaining lower rates of ejaculatory dysfunction and reducing the incidence of stress urinary incontinence.